Esperion Therapeutics, Inc. (ESPR) Stock Rating Reaffirmed by Jefferies Group LLC
Esperion Therapeutics, Inc. (NASDAQ:ESPR)‘s stock had its “buy” rating reaffirmed by analysts at Jefferies Group LLC in a report issued on Monday. They presently have a $85.00 price target on the biopharmaceutical company’s stock. Jefferies Group LLC’s target price suggests a potential upside of 89.99% from the company’s previous close.
Several other equities research analysts have also recently weighed in on ESPR. Zacks Investment Research cut shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, May 1st. ValuEngine raised shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Citigroup Inc. reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, June 22nd. Deutsche Bank AG initiated coverage on shares of Esperion Therapeutics in a research report on Friday, June 23rd. They issued a “buy” rating and a $48.00 price target for the company. Finally, BidaskClub raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, June 25th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the stock. Esperion Therapeutics presently has an average rating of “Hold” and a consensus price target of $44.65.
Esperion Therapeutics (NASDAQ:ESPR) traded down 1.375% during trading on Monday, hitting $44.125. 149,629 shares of the stock traded hands. The firm’s market cap is $996.92 million. Esperion Therapeutics has a 12 month low of $9.40 and a 12 month high of $57.38. The firm has a 50-day moving average price of $47.33 and a 200 day moving average price of $36.54.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, missing the consensus estimate of ($1.67) by $0.25. During the same period in the previous year, the firm earned ($0.62) EPS. On average, equities analysts forecast that Esperion Therapeutics will post ($7.39) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Esperion Therapeutics, Inc. (ESPR) Stock Rating Reaffirmed by Jefferies Group LLC” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/21/esperion-therapeutics-inc-espr-stock-rating-reaffirmed-by-jefferies-group-llc.html.
A number of large investors have recently bought and sold shares of the stock. BB Biotech AG boosted its stake in Esperion Therapeutics by 7.5% in the second quarter. BB Biotech AG now owns 1,513,542 shares of the biopharmaceutical company’s stock worth $70,047,000 after buying an additional 105,000 shares during the last quarter. State Street Corp raised its position in shares of Esperion Therapeutics by 264.6% in the second quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock worth $69,721,000 after buying an additional 1,093,292 shares during the last quarter. FMR LLC raised its position in shares of Esperion Therapeutics by 2.3% in the second quarter. FMR LLC now owns 1,338,588 shares of the biopharmaceutical company’s stock worth $61,950,000 after buying an additional 30,000 shares during the last quarter. Boxer Capital LLC bought a new position in shares of Esperion Therapeutics during the first quarter worth about $45,020,000. Finally, Discovery Capital Management LLC CT raised its position in shares of Esperion Therapeutics by 152.9% in the second quarter. Discovery Capital Management LLC CT now owns 965,059 shares of the biopharmaceutical company’s stock worth $44,663,000 after buying an additional 583,529 shares during the last quarter. 85.39% of the stock is owned by institutional investors.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.